• Report Adverse Event or Product Quality Complaint
  • Global Site
AstraZeneca Medical Information
  • Prescribing Information
  • Resources
    • Congress Library
    • Our Pipeline
    • AZ Clinical Trials
    • Externally Sponsored Scientific Research
  • Connect
    • Send MIR
    • Give Feedback

Search Medical Information

American College of Cardiology (ACC) - 2025

March 29 - 31, 2025

  1. Hypertension
  2. Cardiovascular & Kidney Disease
  3. Lokelma (Sodium zirconium cyclosilicate)
  4. ATTR Amyloidosis
  5. Chronic Obstructive Pulmonary Disease
  6. Dyslipidemia

pdf

Subclinical primary aldosteronism and risk of cardiovascular outcomes the atherosclerosis risk in communities study

pdf

Inadequately controlled hypertension - patient profiles in USA and UK: insights from the EnligHTN study

html

Galectin-3 and cardiovascular and kidney outcomes: individual patient data meta-analysis of 74,358 patients from 5 multinational clinical trials

pdf

Patterns of hyperkalemia recurrence among heart failure patients

pdf

Risk factors of hyperkalemia recurrence among heart failure

pdf

Health care resource use prior to diagnosis in patients with ATTR amyloidosis - results from the OverTTuRe study

pdf

Variation in disease severity, ATTR-specific drug treatment rates, and time to treatment in newly diagnosed transthyretin amyloidosis-cardiomyopathy in the Medicare fee-for-service population

pdf

INSIGHT-CM: Interpretable natural language processing system for identification of transthyretin amyloidosis cardiomyopathy using machine learning and deep learning

pdf

Variation in cardiopulmonary risk among 3.4 million Medicare beneficiaries with chronic obstructive pulmonary disease by race/ethnicity and income

pdf

Efficacy and safety of AZD0780, an oral small molecule PCSK9 inhibitor for treatment of hypercholesterolemia: Results from a Ph2b randomized placebo-controlled clinical trial

Need Help?

Contact Us

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

AstraZeneca Logo

This platform is provided as service to healthcare professionals by AstraZeneca Philippines, for medical educational purposes only.

©2024 AstraZeneca. All rights reserved.

PH-10554.

Last Updated 5/24

Contact Us

About Us

AstraZeneca.com

Survey Feedback

Privacy Notice

Legal Notice

Cookie Notice

Global Site

Report Adverse Event or Product Quality Complaint

Privacy NoticeLegal NoticeCookie Notice

Welcome to AstraZeneca Philippines Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the Philippines, for medical educational purposes only. AstraZeneca does not engage in the promotion of unregistered products or unapproved indications. The dissemination of this information may be subject to different medical and regulatory requirements in other countries

Are you a healthcare professional practicing in the Philippines?

No